Document:

EX-10.70

AMENDMENT NO.1 TO EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment No. 1 to Executive Employment Agreement (this “Amendment”) is made as of the
27th day of November, 2008, by and between STAAR Surgical Company, a Delaware corporation
(“STAAR”), and Barry G. Caldwell (“the Executive”), in reference to the following:

RECITALS

A. The Executive and STAAR are parties to an Executive Employment Agreement dated
November 27, 2007 (the “Agreement”), whereby STAAR agreed to retain the services of the Executive
as its Chief Executive Officer, and the Executive agreed to render such services.

B. STAAR and the Executive wish to modify the terms of the Agreement so that the base salary
is payable by STAAR in cash subject to an election by the Executive to receive a portion of his
salary in the form of common stock.

NOW, THEREFORE, in consideration of the premises stated above, the mutual promises contained
herein, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Company and the Executive agree as follows:

AGREEMENT

1. Section 3.1 of the Agreement is hereby amended and restated in its entirety as follows:

“3.1 Base Compensation.

“(a) Base Salary. Subject to any election made pursuant to
Section 3.1(b), STAAR shall pay the Executive a base salary (the “Initial
Base Salary”) at the annual rate of $400,000, to be paid on a bi-weekly basis in
cash by check, wire transfer or similar means. The Executive’s annual salary will
be reviewed annually by the Board for the purpose of determining whether, at the
sole discretion of the Board, the Executive’s salary shall be increased. (In this
Agreement the term “Base Salary” shall mean, as of any date, the Initial Base
Salary, plus all discretionary increases of annual pay made by the Board up to and
including such date.)

“(b) Equity Compensation Portion of Base Salary. Subject to the
approval of the Board, during the Term the Executive may elect to receive a portion
of his Base Salary to be earned during the next Renewal Term in the form of
restricted shares of STAAR’s common stock (the “Stock Portion”) as follows. At the
first regularly scheduled meeting of the Board following the filing of STAAR’s
Quarterly Report on Form 10-Q for the third fiscal quarter (the “Election Date”),
the Executive may request to receive a specified amount of his Base Salary as the
Stock Portion. If approved by the Board, the Executive shall receive, on, or as
soon as practicable after, the anniversary of the Effective Date, restricted shares
of STAAR’s common stock pursuant to the 2003 Omnibus Equity Incentive Plan or such
similar equity incentive plan of the Company then in effect (the “Plan”), in a
number equal to the Stock Portion divided by the Fair Market Value (as defined in
the Plan) of STAAR’s common stock on the Election Date. Any Stock Portion received
by the Executive shall be subject to vesting restrictions pursuant to the form of
Restricted Stock Agreement appended to the Plan, and shall vest in twelve equal
monthly installments at the end of each full calendar month following the
anniversary of the Effective Date.”

2. Section 3.2 of the Agreement is hereby amended by replacing the words:

“In addition to the base salary described above, the Executive will be eligible for
an annual performance bonus of up to 60% of annual base compensation (including for
such purpose the equity compensation provided pursuant to Section 3.1(b) at a value
of $100,000)”

with the following words:

“In addition to the Base Salary, the Executive will be eligible for an annual
performance bonus of up to 60% of the Base Salary”

3. Section 5.10(a) of the Agreement is hereby amended by replacing the words:

“base compensation at the rate in effect on the Termination Date (including for such
purpose at a value of $100,000 per year the equity compensation payable under
Section 3.1(b))”

with the following words:

“Base Salary in effect on the Termination Date.”

4. Except as expressly modified by this Amendment, all terms, conditions and provisions of the
Agreement shall continue in full force and effect as set forth in the Agreement. Except as
otherwise modified or defined herein, all capitalized terms in this Amendment have the same
meanings as set forth in the Agreement. In the event of a conflict between the terms and
conditions of the Agreement and the terms and conditions of this Amendment, the terms and
conditions of this Amendment shall prevail. Each party represents and warrants to the other party
that this Amendment has been duly authorized, executed and delivered by it and constitutes a valid
and legally binding agreement with respect to the subject matter contained herein. Each party
agrees that the Agreement, as amended by this Amendment, constitutes the complete and exclusive
statement of the agreement between the Parties, and supersedes all prior proposals and
understandings, oral and written, relating to the subject matter contained herein. This Amendment
shall not be modified or rescinded except in a writing signed by the Parties. This Amendment may be
executed manually or by facsimile signature in two or more counterparts, each of which shall be
deemed an original, and all of which together shall constitute but one and the same instrument.

The next page is the signature page.

1

IN WITNESS WHEREOF, the parties have executed this Amendment No. 1 to Executive Employment
Agreement, effective on the date first written above.

EXECUTIVE EMPLOYEE

/s/ Barry G. Caldwell

Barry G. Caldwell

STAAR SURGICAL COMPANY

/s/ Charles Kaufman

Charles Kaufman

Vice President and Secretary

2EX-10.1

SETTLEMENT AGREEMENT

I. PARTIES

This Settlement Agreement (Agreement) is entered into among the United States of America,
acting through the United States Department of Justice and on behalf of the Department of Veteran’s
Affairs (“VA”), the Department of Defense (“DOD”), and the Public Health Service (“PHS”), part of
the Department of Health and Human Services (“HHS”) (collectively the “United States”); Christopher
Foley, Susan Purdue, and MedQuist Inc.; (hereafter referred to as “the Parties”), through their
authorized representatives.

II. PREAMBLE

As a preamble to this Agreement, the Parties agree to the following:

A. MedQuist provides medical transcription services to private and government clients alike.
From 1998 onward, MedQuist provided medical transcription services to several federal government
clients, including the VA, DOD, and PHS. Certain contracts between MedQuist and the United States
called for MedQuist to bill according to a standard established by the American Association of
Medical Transcriptionists called the “AAMT line.”

B. Christopher Foley (“Foley”) is an individual resident of Georgia. On August 30, 2004,
Foley filed a qui tam action in the United States District Court for the District
of Massachusetts captioned United States ex rel. Foley v. MedQuist Inc., Case No. CV 04-11821-PBS
(D. Mass.) (hereinafter “the Foley Action”).

C. Susan Purdue (“Purdue”) is an individual resident of North Carolina. On March 24, 2005, Purdue
filed a qui tam action in the United States District Court for the Western District
of North Carolina captioned United States ex rel. Purdue v. MedQuist Inc., Case No.1:05CV69
(W.D.N.C.). This case was subsequently transferred to the United States District Court for the
District of Massachusetts and assigned Case No. CV 06-00678-PBS (D. Mass.)

D. The United States contends that it has certain civil claims, as specified in Paragraph 2,
against MedQuist for knowingly engaging in the following conduct during the period from 1998 to
2004: Overbilling VA, DOD, and PHS (i) as to that group of contracts specifying the AAMT character
counting methodology, by inflating the number of lines billed to the Government by use of a factor,
ratio, and/or multiplier instead of applying the contractually prescribed method, and (ii) as to
certain VA contracts administered by MedQuist’s Asheville, NC office and specifying a non-AAMT
character counting methodology, by billing more than the contractually specified method prescribed
(hereinafter collectively referred to as the “Covered Conduct.”).

E. This Agreement is neither an admission of liability by MedQuist nor a concession by the
United States that its claims are not well-founded.

F. The Government has intervened for purposes of settlement in the Foley Action and the Purdue
Action as to those claims that constitute the Covered Conduct (the “Settled Claims”), and it has
declined to intervene as to all other claims in the Foley Action and the Purdue Action (the
“Declined Claims”).

G. To avoid the delay, uncertainty, inconvenience, and expense of protracted litigation of the
above claims, the Parties hereto reach a full and final settlement pursuant to the Terms and
Conditions below.

1

III. TERMS AND CONDITIONS

1. MedQuist agrees to pay to the United States $6.6 million (the “Settlement Amount”), of
which $5 million is associated with the Foley Action and $1.6 million is associated with the Purdue
Action. Payment shall be made as follows:

a. MedQuist agrees to pay the full Settlement Amount to the United States by electronic funds
transfer pursuant to written instructions to be provided by the United States Attorney’s Office,
within ten (10) days of the Effective Date of this Agreement.

b. Contingent upon the United States receiving the Settlement Amount from MedQuist and as soon
as feasible after receipt, the United States agrees to pay $450,000 to Foley

in connection with the allegations set forth in paragraph II.D.i of this Agreement, and $144,000 to
Purdue in connection with the allegations set forth in paragraph II.D.ii of this Agreement, each by
electronic funds transfer pursuant to instructions to be provided by their respective counsel.

2. Subject to the exceptions in Paragraph 4 (concerning excluded claims), below, in
consideration of the obligations of MedQuist in this Agreement, conditioned upon MedQuist’s full
payment of the Settlement Amount, the United States (on behalf of itself, its officers, agents,
agencies, and departments) agrees to release MedQuist, as well as its officers, directors, agents,
servants, and employees from any civil or administrative monetary claim the United States has or
may have for the Covered Conduct under the False Claims Act, 31 U.S.C. §§ 3729-3733; the Program
Fraud Civil Remedies Act, 31 U.S.C. §§ 3801-3812; or the common law theories of breach of contract,
payment by mistake, unjust enrichment, and fraud.

2

3. Subject to the exceptions in Paragraph 4 (concerning excluded claims), below, in
consideration of the obligations of MedQuist in this Agreement, conditioned upon MedQuist’s full
payment of the Settlement Amount,

a. Foley, for himself and for his heirs, successors, attorneys, agents, and assigns, agrees to
release MedQuist from any civil monetary claim the United States has or may have for the Covered
Conduct under the False Claims Act, 31 U.S.C. §§ 3729-3733.

b. Purdue, for herself and for her heirs, successors, attorneys, agents, and assigns, agrees
to release MedQuist from any civil monetary claim the United States has or may have for the Covered
Conduct under the False Claims Act, 31 U.S.C. §§ 3729-3733.

4. Notwithstanding any term of this Agreement, specifically reserved and excluded from the
scope and terms of this Agreement as to any entity or person (including MedQuist) are the following
claims of the United States:

a. Any civil, criminal, or administrative liability arising under Title 26, U.S. Code
(Internal Revenue Code);

b. Any criminal liability;

c. Any administrative liability, including the suspension and debarment rights of any federal
agency;

d. Any liability to the United States (or its agencies) for any conduct other than the Covered
Conduct; and

e. Any liability based upon such obligations as are created by this Agreement.

3

5. Foley and Purdue and their heirs, successors, attorneys, agents, and assigns agree not to
object to this Agreement and agree and confirm that this Agreement is fair, adequate, and
reasonable under all the circumstances, pursuant to 31 U.S.C. § 3730(c)(2)(B), and, conditioned
upon their receipt of their respective Relator’s shares, Foley and Purdue, for themselves
individually, and their heirs, successors, attorneys, agents, and assigns, fully and finally
release, waive, and forever discharge the United States, its officers, agents, and employees, from
any claims arising from or relating to 31 U.S.C. § 3730; from any claims arising from the filing of
the Civil Action; and from any other claims for a share of the Settlement Amount; and in full
settlement of any claims Foley or Purdue may have under this Agreement. This Agreement does not
resolve or in any manner affect any claims the United States has or may have against the Relators
arising under Title 26, U.S. Code (Internal Revenue Code), or any claims arising under this
Agreement.

6. Foley’s claim for attorney’s fees, costs, and expenses pursuant to 31 U.S.C. § 3730(d)(1),
and Purdue’s claims for attorney’s fees, costs, and expenses pursuant to 31 U.S.C. § 3730(d)(1) and
for wrongful termination pursuant to 31 U.S.C. § 3730(h), are not the subject of this Agreement and
will be resolved, if at all, via separate agreements with MedQuist.

7. MedQuist waives and shall not assert any defenses MedQuist may have to any criminal prosecution
or administrative action relating to the Covered Conduct that may be based in whole or in part on a
contention that, under the Double Jeopardy Clause in the Fifth Amendment of the Constitution, or
under the Excessive Fines Clause in the Eighth Amendment of the Constitution, this Agreement bars a
remedy sought in such criminal prosecution or administrative action. Nothing in this paragraph or
any other provision of this Agreement

4

constitutes an agreement by the United States
concerning the characterization of the Settlement Amount for purposes of the Internal Revenue laws,
Title 26 of the United States Code.

8. MedQuist fully and finally releases the United States, its agencies, employees, servants,
and agents from any claims (including attorney’s fees, costs, and expenses of every kind and
however denominated) that MedQuist has asserted, could have asserted, or may assert in the future
against the United States, and its agencies, employees, servants, and agents, related to the
Covered Conduct and the United States’ investigation and prosecution thereof.

9. MedQuist fully and finally releases Foley and Purdue from any claims (including attorney’s
fees, costs, and expenses of every kind and however denominated) that MedQuist has asserted, could
have asserted, or may assert in the future against either of them, related to the Covered Conduct
and the investigation and prosecution thereof by Foley and/or Purdue.

10. MedQuist agrees to the following:

a. Unallowable Costs Defined: that all costs (as defined in the Federal
Acquisition Regulation, 48 C.F.R. § 31.205-47) incurred by or on behalf of MedQuist, and its
present or former officers, directors, employees, shareholders, and agents in connection with:

(1) the matters covered by this Agreement;

(2) the United States’ audit(s) and civil investigation(s) of the matters covered by this
Agreement;

(3) MedQuist’s investigation, defense, and corrective actions undertaken in response to the
United States’ audit(s) and civil investigation(s) in connection with the matters covered by this
Agreement (including attorney’s fees);

(4) the negotiation and performance of this Agreement;

5

(5) the payment MedQuist makes to the United States pursuant to this Agreement and any
payments that MedQuist may in the future make to Foley or Purdue (if any), including costs and
attorneys fees, are “Unallowable Costs” for government contracting purposes (hereinafter referred
to as “Unallowable Costs”).

b. Future Treatment of Unallowable Costs: Unallowable Costs will be separately
determined and accounted for by MedQuist, and MedQuist shall not charge such Unallowable Costs
directly or indirectly to any contracts with the United States.

c. Treatment of Unallowable Costs Previously Submitted for Payment: MedQuist further
agrees that within 90 days of the Effective Date of this Agreement it shall identify any
unallowable costs (as defined in this Paragraph) included in payments previously sought by MedQuist
or any of its subsidiaries or affiliates from the United States. MedQuist agrees that the United
States, at a minimum, shall be entitled to recoup from MedQuist any overpayment plus applicable
interest and penalties as a result of the inclusion of such Unallowable Costs in any such payments.
Any payments due shall be paid to the United States pursuant to the direction of the Department of
Justice and/or the affected agencies. The United States reserves its rights to disagree with any
calculations submitted by MedQuist or any of its subsidiaries or affiliates regarding any
Unallowable Costs included in payments previously sought by MedQuist or the effect of any such
Unallowable Costs on the amount of such payments.

d. Nothing in this Agreement shall constitute a waiver of the rights of the United States to
audit, examine, or re-examine MedQuist’s books and records to determine that no Unallowable Costs
have been claimed in accordance with the provisions of this Paragraph.

6

11. This Agreement is intended to be for the benefit of the Parties only. The Parties do not
release any claims against any other person or entity.

12. MedQuist warrants that it has reviewed its financial situation and that it currently is
solvent within the meaning of 11 U.S.C. §§ 547(b)(3) and 548(a)(1)(B)(ii)(I), and shall remain
solvent following payment to the United States of the Settlement Amount. Further, the Parties
warrant that, in evaluating whether to execute this Agreement, they (a) have intended that the
mutual promises, covenants, and obligations set forth constitute a contemporaneous exchange for new
value given to MedQuist, within the meaning of 11 U.S.C. § 547(c)(1), and (b) conclude that these
mutual promises, covenants, and obligations do, in fact, constitute such a contemporaneous
exchange. Further, the Parties warrant that the mutual promises, covenants, and obligations set
forth herein are intended to and do, in fact, represent a reasonably equivalent exchange of value
that is not intended to hinder, delay, or defraud any entity to which MedQuist was or became
indebted to on or after the date of this transfer, within the meaning of 11 U.S.C. § 548(a)(1).

13. Upon receipt of the payments described in Paragraph 1, above, the United States and Foley
and Purdue shall promptly sign and file in, respectively, the Foley Action and the Purdue Action a
Joint Stipulation of Dismissal of the Settled Claims with prejudice and of the Declined Claims with
prejudice to Foley and Purdue and without prejudice as to the United States. The Stipulation of
Dismissal shall expressly provide that the Court shall retain jurisdiction in each case as to
issues not resolved by this Agreement, including issues of relator’s entitlement to attorney’s
fees.

7

14. Except as may be separately determined or agreed upon in connection with claim(s) by Foley
and/or Purdue for attorney’s fees under 31 U.S.C. § 3730(d)(1), each Party shall bear its own legal
and other costs incurred in connection with this matter, including the preparation and performance
of this Agreement.

15. MedQuist represents that this Agreement is freely and voluntarily entered into without any
degree of duress or compulsion whatsoever.

16. Foley and Purdue each represent that this Agreement is freely and voluntarily entered into
without any degree of duress or compulsion whatsoever.

17. This Agreement is governed by the laws of the United States. The Parties agree that the
exclusive jurisdiction and venue for any dispute arising between and among the Parties under this
Agreement is the United States District Court for the District of Massachusetts.

18. For purposes of construction, this Agreement shall be deemed to have been drafted by all
Parties to this Agreement and shall not, therefore, be construed against any Party for that reason
in any subsequent dispute.

19. This Agreement constitutes the complete agreement between the Parties. This Agreement may
not be amended except by written consent of the Parties.

20. The individuals signing this Agreement on behalf of MedQuist represent and warrant that
they are authorized by MedQuist to execute this Agreement. The individuals signing this Agreement
on behalf of Foley and Purdue represent and warrant that they are authorized respectively by Foley
and Purdue to execute this Agreement. The United States signatories represent that they are signing
this Agreement in their official capacities and that they are authorized to execute this Agreement.

8

21. This Agreement may be executed in counterparts, each of which constitutes an original and
all of which constitute one and the same Agreement.

22. This Agreement is binding on MedQuist’s successors, transferees, heirs, and assigns.

23. This Agreement is binding on Foley’s and Purdue’s respective successors, transferees,
heirs, and assigns.

24. All parties consent to the United States’ disclosure of this Agreement, and information
about this Agreement, to the public.

25 This Agreement is effective on the date of signature of the last signatory to the Agreement
(Effective Date of this Agreement). Facsimiles of signatures shall constitute acceptable, binding
signatures for purposes of this Agreement.

THE UNITED STATES OF AMERICA

	 	 	 
	DATED: 11/25/2008

	 	BY: /s/ Shannon Kelley
	
 
	 	 
	
 
	 	Shannon Kelley

Assistant United States Attorney

District of Massachusetts
	DATED: 11/25/2008

	 	BY: /s/ Jay D. Majors
	
 
	 	 
	
 
	 	Jay D. Majors

Trial Attorney

Commercial Litigation Branch

Civil Division

United States Department of Justice

9

MedQuist Inc.

	 	 	 
	DATED: 11/25/2008

	 	BY: /s/ Mark R. Sullivan
	
 
	 	 
	
 
	 	Mark Sullivan, Esq.

General Counsel

MedQuist Inc.
	DATED: 11/25/2008

	 	BY: /s/ Thomas M. Buchanan
	
 
	 	 
	
 
	 	Thomas M. Buchanan, Esq.

Winston & Strawn

Counsel for MedQuist Inc.

10

	 	 	CHRISTOPHER FOLEY — Relator

	 	 	 
	DATED: 11/22/2008

	 	BY: /s/ Christopher Foley
	
 
	 	 
	
 
	 	Christopher Foley
	DATED: 11/22/2008

	 	BY: /s/ Mark Hogge
	
 
	 	 
	
 
	 	Mark Hogge, Esq.

Greenberg Traurig

Counsel for Christopher Foley

11

	 	 	SUSAN PURDUE — Relator

	 	 	 
	DATED: 11/25/2008

	 	BY: /s/ Susan Purdue
	
 
	 	 
	
 
	 	Susan Purdue
	DATED: 11/25/2008

	 	BY: /s/ Adam Bull
	
 
	 	 
	
 
	 	Adam Bull, Esq.

Bull & Reinhardt

Counsel for Susan Purdue

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}]]